Page 122 - Read Online
P. 122
Page 34 of 34 West et al. Rare Dis Orphan Drugs J 2024;3:22 https://dx.doi.org/10.20517/rdodj.2023.61
disorders. EMBO Mol Med 2022;14:e14297. DOI PubMed PMC
188. Romano R, Park H, Pios A, Brennan T, Selby MJ, Boyle K. Development of a B cell protein factory to produce sustained therapeutic
levels of alpha-galactosidase a for the treatment of Fabry disease. Mol Genet Metab 2023;138:107298. DOI
189. Ter Huurne M, Parker BL, Liu NQ, et al. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from
Fabry-affected individuals. Am J Hum Genet 2023;110:1600-5. DOI PubMed PMC
190. Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: progress, challenges, and outlooks on gene-editing.
Mol Genet Metab 2021;134:117-31. DOI
191. Takahashi H, Hirai Y, Migita M, et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-
mediated muscle-directed gene transfer. Proc Natl Acad Sci USA 2002;99:13777-82. DOI PubMed PMC
